Serum metabolomic alterations in multiple myeloma revealed by targeted and untargeted metabolomics approaches: a pilot study. Issue 51 (18th September 2019)

• Record Type: Journal Article
• Authors: Chanukuppa, Venkatesh; More, Tushar H.; Taunk, Khushman; Taware, Ravindra; Chatterjee, Tathagata; Sharma, Sanjeevan; Rapole, Srikanth
• Is Part Of: RSC advances. Volume 9:Issue 51(2019)
• Page Start: 29522
• Page End: 29532
• Publication Date: 2019-09-18
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/c9ra04458b
• Languages: English
• ISSNs: 2046-2069

Abstract

Abstract : This study presents the potential of serum metabolomics approach towards the segregation of multiple myeloma cohort from healthy controls. Abstract : Multiple myeloma (MM) is the second most prevalent hematological malignancy characterized by rapid proliferation of plasma cells, which leads to overproduction of antibodies. MM affects around 15% of all hemato-oncology cases across the world. The present study involves identification of metabolomic alterations in the serum of an MM cohort compared to healthy controls using both LC-MRM/MS based targeted and GC-MS based untargeted approaches. Several MM specific serum metabolomic signatures were observed in this study. A total of 54 metabolites were identified as being significantly altered in MM cohort, out of which, 26 metabolites were identified from LC-MRM/MS based targeted analysis, whereas 28 metabolites were identified from the GC-MS based untargeted analysis. Receiver operating characteristic (ROC) curve analysis demonstrated that six metabolites each from both the datasets can be projected as marker metabolites to discriminate MM subjects with higher specificity and sensitivity. Moreover, pathway analysis deciphered that several metabolic pathways were altered in MM including pyrimidine metabolism, purine metabolism, amino acid metabolism, nitrogen metabolism, sulfur metabolism, and the citrate cycle. Comprehensively, this study contributes valuable information regarding MM induced serum metabolite alterations and their pathways, which could offer further insights into this cancer.